RPRX- Dew, in the line of your CFO = canary in a coal mine "warning signs for biotech investors" thought process,(which as a previous Big 4 auditor, i never bought into for biotech co's with no earnings) what exactly are you expecting the FDA to balk on concerning the use of Proellex in 50mg and 25mg doses to tx anemia for a total of 3 mo? If you were holding RPRX and people questioned the new IND smelling fishy, IMO you would immediately dismiss it as nonsense since longer durations of dosage in chronic indications had already been granted successful INDs previously... I don't see how anemia is high risk? I'd like YOU to give US some scenarios instead of asking RPRX longs to explain what could easily be a matter of organizational paperwork. Give me some scenarios here, please.
PS - a CFO leaving is a warning sign, but in profitless biotechs there is less pressure to manipulate or cookie jar earnings or accruals. It likely has little to do w financials, and more to do with opportunities elsewhere, unhappy managerial attitudes w/n a co, or a dim outlook clinically (and ultimately financially) IMO.
